中青报·中青网记者 刘世昕 得益于北京市12月30日发布的两项医疗健康+AI政策，北京市海淀区甘家口社区卫生服务中心的AI诊疗 能力近期可能再上台阶；鹰瞳科技这家做眼底病变大数据模型的企业将有更畅通的机会和医疗机构合 作，获得更好的落地场景。 这两项政策分别是《北京市支持医疗健康领域人工智能应用发展行动计划（2026-2027年）》（以下简 称《行动计划》）和《北京市医疗健康领域支持人工智能产业创新发展若干措施（2026-2027年）》 （以下简称《若干措施》）。 《行动计划》明确，到2027年，北京的人工智能技术在疾病防、筛、管、救、治、康全流程得到广泛应 用，全市医疗卫生机构普遍开展人工智能产品落地应用，百姓将享有更优质的医疗服务。《若干措施》 则从聚焦临床需求场景、强化数据治理、优化支撑体系、强化政策保障4个维度出发，锚定到2027年， 北京在医疗健康领域建成"需求精准对接、数据高效流通、技术快速转化、生态协同发展"的人工智能产 业支撑体系。 《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》提出，全面实施"人工智能+"行 动，加强人工智能同产业发展、文化建设、民生保障、社会治理相结合，全方位 ...

Core Viewpoint - Jiuzhitang (000989) is making significant progress in both traditional Chinese medicine and innovative drug development, particularly in stem cell therapy and new drug projects, as evidenced by its recent financial performance and ongoing clinical trials [1][2][3] Financial Performance - For the first half of 2025, Jiuzhitang reported a revenue of 1.265 billion yuan and a net profit attributable to shareholders of 144 million yuan, with operating cash flow increasing by 191.72% compared to the same period last year [1] Corporate Governance - In January 2025, the Heilongjiang Provincial State-owned Assets Supervision and Administration Commission became the new controlling shareholder of Jiuzhitang. In July, the company appointed Wang Lifeng as the new chairman and legal representative [1] Innovation and R&D Progress - Jiuzhitang is optimizing its organizational structure and accelerating marketing reforms while advancing its innovative research and development efforts, particularly in stem cell projects and drug candidates YB209 and YB211 [1] - The YB209 project, a novel anticoagulant drug with complete independent intellectual property rights, has completed method development and verification for immunogenicity studies, with Phase I clinical trials nearing completion [1] - The YB211 project, targeting antibiotic-resistant bacterial infections, has initiated Phase II clinical trials with 44 subjects enrolled, following the completion of clinical sample preparation and toxicity tests [1] Stem Cell Research - Jiuzhitang's subsidiary, Beijing Meike, has completed enrollment for 45 subjects in a Phase IIa clinical trial for ischemic stroke treatment using allogeneic bone marrow mesenchymal stem cells. Additionally, a clinical trial for treating autoimmune pulmonary alveolar proteinosis has enrolled 10 subjects [2] - Beijing Meike has received approval for a clinical trial using bone marrow mesenchymal stem cell injection for autism treatment, further expanding the application prospects of its stem cell technology [2] Commitment to Traditional Chinese Medicine - Jiuzhitang is actively engaged in the innovation and development of new traditional Chinese medicines, with ongoing research on classic formulas YB106 and YB107, and real-world studies for products like Shuxuetong injection [3] - The company is conducting clinical evidence-based research on several key products, which will clarify their therapeutic advantages and support the upgrade of its traditional Chinese medicine offerings [3]